Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EVH Stock Forecast 2025-2026
$8.65
Current Price
$996.73M
Market Cap
Buy 13
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to EVH Price Targets
+131.2%
To High Target of $20.00
+73.4%
To Median Target of $15.00
+4.0%
To Low Target of $9.00
EVH Price Momentum
+2.4%
1 Week Change
+0.3%
1 Month Change
-60.8%
1 Year Change
-23.1%
Year-to-Date Change
-74.3%
From 52W High of $33.63
+22.5%
From 52W Low of $7.06
📊 TOP ANALYST CALLS
Did EVH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Evolent Health is one of their latest high-conviction picks.
Latest EVH Stock Price Targets & Analyst Predictions
Based on our analysis of 24 Wall Street analysts, EVH has a bullish consensus with a median price target of $15.00 (ranging from $9.00 to $20.00). Currently trading at $8.65, the median forecast implies a 73.4% upside. This outlook is supported by 13 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jailendra Singh at Truist Securities, projecting a 131.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EVH Analyst Ratings
13
Buy
1
Hold
0
Sell
EVH Price Target Range
Low
$9.00
Average
$15.00
High
$20.00
Current: $8.65
Latest EVH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EVH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $15.00 |
| May 9, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $15.00 |
| Apr 28, 2025 | JMP Securities | Constantine Davides | Market Outperform | Reiterates | $13.00 |
| Apr 10, 2025 | Truist Securities | Jailendra Singh | Buy | Maintains | $14.00 |
| Mar 10, 2025 | JP Morgan | Anne Samuel | Overweight | Maintains | $12.00 |
| Feb 24, 2025 | Citizens Capital Markets | Constantine Davides | Market Outperform | Maintains | $13.00 |
| Feb 21, 2025 | Piper Sandler | Jessica Tassan | Overweight | Reiterates | $16.00 |
| Feb 21, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $15.00 |
| Feb 14, 2025 | JMP Securities | Constantine Davides | Market Outperform | Reiterates | $12.00 |
| Feb 12, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $15.00 |
| Jan 28, 2025 | JP Morgan | Anne Samuel | Overweight | Maintains | $13.00 |
| Jan 24, 2025 | Oppenheimer | Jeff Jones | Outperform | Maintains | $18.00 |
| Jan 23, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $16.00 |
| Jan 22, 2025 | Truist Securities | Jailendra Singh | Buy | Maintains | $15.00 |
| Jan 21, 2025 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $12.00 |
| Jan 16, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $14.00 |
| Jan 15, 2025 | Needham | Ryan MacDonald | Buy | Reiterates | $15.00 |
| Jan 14, 2025 | RBC Capital | Sean Dodge | Outperform | Maintains | $17.00 |
| Jan 13, 2025 | Truist Securities | Jailendra Singh | Buy | Maintains | $20.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $18.00 |
Evolent Health Inc. (EVH) Competitors
The following stocks are similar to Evolent Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EVH
Evolent Health
mkt cap
970.90M
Evolent Health Inc. (EVH) Financial Data
Evolent Health Inc. has a market capitalization of $996.73M with a P/E ratio of -10.7x. The company generates $2.40B in trailing twelve-month revenue with a -4.5% profit margin.
Revenue growth is -24.4% quarter-over-quarter, while maintaining an operating margin of +0.4% and return on equity of -9.2%.
Valuation Metrics
Market Cap
$996.73M
Enterprise Value
$1.80B
P/E Ratio
-10.7x
PEG Ratio
5.9x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-24.4%
Gross Margin
+21.2%
Operating Margin
+0.4%
Net Margin
-4.5%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+24.6%
Current Ratio
1.0x
Debt/Equity
77.1x
ROE
-9.2%
ROA
0.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Evolent Health Inc. (EVH) Business Model
About Evolent Health Inc.
What They Do
Provides healthcare solutions for value-based care.
Business Model
Evolent Health partners with healthcare providers to enhance patient care through innovative technology and services. It generates revenue by offering a comprehensive platform that integrates clinical and administrative tools, helping clients transition from fee-for-service to value-based care models, thus improving patient outcomes and reducing costs.
Additional Information
Founded in 2011 and headquartered in Arlington, Virginia, Evolent Health serves a diverse range of clients, including hospitals, health systems, and physician organizations. The company plays a significant role in the healthcare sector by facilitating personalized and efficient care strategies, and it is well-positioned to capitalize on the growing focus on cost-effective health management.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
4,500
CEO
Mr. Seth Barrie Blackley
Country
United States
IPO Year
2015
Website
www.evolent.comEvolent Health Inc. (EVH) Latest News & Analysis
Latest News
Quick Summary
Evolent Health, Inc. (NYSE:EVH) will hold its Q1 2025 earnings conference call on May 8, 2025, at 5:00 PM ET, featuring CEO Seth Blackley and CFO John Johnson.
Why It Matters
Evolent Health's Q1 earnings call provides insights into financial performance and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Evolent Announces First Quarter 2025 Results
1 month ago
Quick Summary
Evolent Health (NYSE: EVH) reported strong Q1 2025 results and confirmed its full-year revenue and Adjusted EBITDA outlook, signaling performance at the high end of expectations.
Why It Matters
Evolent Health's strong Q1 results and reaffirmed full-year guidance signal growth potential, which can boost investor confidence and positively impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Evolent Health (EVH) reported its quarterly revenue and EPS for March 2025, suggesting a comparison with Wall Street estimates and prior year metrics is important for evaluation.
Why It Matters
Evolent Health's revenue and EPS performance relative to Wall Street estimates and year-ago figures indicates growth trends, impacting investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Evolent Health (EVH) Q1 Earnings Lag Estimates
1 month ago
Quick Summary
Evolent Health (EVH) reported Q3 earnings of $0.06 per share, below the Zacks estimate of $0.09, and down from $0.34 per share year-over-year.
Why It Matters
Evolent Health's earnings miss and significant decline from the previous year may signal operational struggles, potentially impacting stock performance and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Negative
Wall Street Analysts Believe Evolent Health (EVH) Could Rally 53.33%: Here's is How to Trade
1 month ago
Quick Summary
Wall Street analysts project a 53.3% upside for Evolent Health (EVH), supported by positive earnings estimate revisions.
Why It Matters
A 53.3% potential upside in Evolent Health's price target suggests strong growth expectations, while positive earnings revisions may boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
1 month ago
Quick Summary
Evolent Health has nominated former CFO of CVS Health and Aetna, Mr. Guertin, to its board, continuing its efforts for board refreshment and enhancing growth and profitability.
Why It Matters
Mr. Guertin's nomination signals a focus on growth and profitability at Evolent, potentially boosting investor confidence and enhancing the company's strategic direction.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EVH Stock
What is Evolent Health Inc.'s (EVH) stock forecast for 2025?
Based on our analysis of 24 Wall Street analysts, Evolent Health Inc. (EVH) has a median price target of $15.00. The highest price target is $20.00 and the lowest is $9.00.
Is EVH stock a good investment in 2025?
According to current analyst ratings, EVH has 13 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EVH stock?
Wall Street analysts predict EVH stock could reach $15.00 in the next 12 months. This represents a 73.4% increase from the current price of $8.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evolent Health Inc.'s business model?
Evolent Health partners with healthcare providers to enhance patient care through innovative technology and services. It generates revenue by offering a comprehensive platform that integrates clinical and administrative tools, helping clients transition from fee-for-service to value-based care models, thus improving patient outcomes and reducing costs.
What is the highest forecasted price for EVH Evolent Health Inc.?
The highest price target for EVH is $20.00 from Jailendra Singh at Truist Securities, which represents a 131.2% increase from the current price of $8.65.
What is the lowest forecasted price for EVH Evolent Health Inc.?
The lowest price target for EVH is $9.00 from at , which represents a 4.0% increase from the current price of $8.65.
What is the overall EVH consensus from analysts for Evolent Health Inc.?
The overall analyst consensus for EVH is bullish. Out of 24 Wall Street analysts, 13 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are EVH stock price projections?
Stock price projections, including those for Evolent Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 3:02 AM UTC